

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



HUTCHMED (China) Limited

和黃醫藥（中國）有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 13)

OVERSEAS REGULATORY ANNOUNCEMENT

This announcement is issued pursuant to Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

Please refer to the attached announcement which has been published by HUTCHMED (China) Limited on the website of the U.K. Regulatory Information Service on March 11, 2026.

By Order of the Board

Edith Shih

Non-executive Director and Company Secretary

Hong Kong, March 11, 2026

As at the date of this announcement, the Directors of the Company are:

Chairman and Non-executive Director:

Dr Dan ELDAR

Executive Directors:

Dr Weiguo SU

*(Chief Executive Officer and
Chief Scientific Officer)*

Mr CHENG Chig Fung, Johnny

*(Acting Chief Executive Officer and
Chief Financial Officer)*

Non-executive Directors:

Ms Edith SHIH

Ms Ling YANG

Independent Non-executive Directors:

Professor MOK Shu Kam, Tony

*(Senior and Lead Independent Non-executive
Director)*

Dr Renu BHATIA

Dr Chaohong HU

Professor TAN Shao Weng, Daniel

Mr WONG Tak Wai

Vesting of awards under the Long Term Incentive Plan

Hong Kong, Shanghai & Florham Park, NJ — Wednesday, March 11, 2026: HUTCHMED (China) Limited (“[HUTCHMED](#)”) (Nasdaq/AIM: HCM; SEHK:13) announces that following the announcement of the 2025 annual results of HUTCHMED on March 5, 2026, the following awards granted under the Long Term Incentive Plan (“LTIP”) on June 5, 2023 to Dr Weiguo Su and Mr Johnny Cheng were vested on March 10, 2026:-

<u>Award Holders</u>	<u>Number of ordinary shares</u>
Person Discharging Managerial Responsibilities	
Dr Weiguo Su (Executive Director, Chief Executive Officer and Chief Scientific Officer)	524,079
Mr Johnny Cheng (Executive Director, Acting Chief Executive Officer and Chief Financial Officer)	202,238
Total	726,317

The notifications set out below are provided in accordance with the requirements of the UK Market Abuse Regulation.

(a) Dr Weiguo Su

1	Details of the person discharging managerial responsibilities/person closely associated		
a)	Name	Dr Weiguo Su	
2	Reason for the notification		
a)	Position/status	Executive Director, Chief Executive Officer and Chief Scientific Officer	
b)	Initial notification/Amendment	Initial notification	
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	HUTCHMED (China) Limited	
b)	LEI	2138006X34YDQ6OBYE79	
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted		
a)	Description of the financial instrument, type of instrument	Ordinary Shares of US\$0.10	
	Identification code	Ordinary Share with DI ISIN: KYG4672N1016	
b)	Nature of the transaction	Vesting of awards granted on June 5, 2023 under HUTCHMED's LTIP	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		Nil	524,079 ordinary shares
d)	Aggregated information — Aggregated volume — Price	N/A	
e)	Date of the transaction	2026-03-10	
f)	Place of the transaction	Outside a trading venue	

(b) Mr Johnny Cheng

1	Details of the person discharging managerial responsibilities/person closely associated						
a)	Name	Mr Johnny Cheng					
2	Reason for the notification						
a)	Position/status	Executive Director, Acting Chief Executive Officer and Chief Financial Officer					
b)	Initial notification/Amendment	Initial notification					
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor						
a)	Name	HUTCHMED (China) Limited					
b)	LEI	2138006X34YDQ6OBYE79					
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted						
a)	Description of the financial instrument, type of instrument	Ordinary Shares of US\$0.10					
	Identification code	Ordinary Share with DI ISIN: KYG4672N1016					
b)	Nature of the transaction	Vesting of awards granted on June 5, 2023 under HUTCHMED's LTIP					
c)	Price(s) and volume(s)	<table><tr><td>Price(s)</td><td>Volume(s)</td></tr><tr><td>Nil</td><td>202,238 ordinary shares</td></tr></table>		Price(s)	Volume(s)	Nil	202,238 ordinary shares
Price(s)	Volume(s)						
Nil	202,238 ordinary shares						
d)	Aggregated information — Aggregated volume — Price	N/A					
e)	Date of the transaction	2026-03-10					
f)	Place of the transaction	Outside a trading venue					

About HUTCHMED

HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit: www.hutch-med.com or follow us on [LinkedIn](#).

CONTACTS**Investor Enquiries**+852 2121 8200 / ir@hutch-med.com**Media Enquiries**

FTI Consulting – Ben Atwell / Tim Stamper Brunswick – Zhou Yi	+44 20 3727 1030 / HUTCHMED@fticonsulting.com +44 7771 913 902 (Mobile) / +44 7779 436 698 (Mobile) +852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com
Panmure Liberum Atholl Tweedie / Emma Earl / Rupert Dearden	Nominated Advisor and Joint Broker +44 20 7886 2500
Cavendish Geoff Nash / Nigel Birks	Joint Broker +44 20 7220 0500
Deutsche Numis Freddie Barnfield / Jeffrey Wong / Duncan Monteith	Joint Broker +44 20 7260 1000